AM-1714

AM-1714
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 1,9-dihydroxy-3-(2-methyloctan-2-yl)-6H-benzo[c]chromen-6-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H26O4
Molar mass354.446 g·mol−1
3D model (JSmol)
  • O=C(O1)C2=C(C=C(O)C=C2)C3=C1C=C(C(C)(C)CCCCCC)C=C3O
  • InChI=1S/C22H26O4/c1-4-5-6-7-10-22(2,3)14-11-18(24)20-17-13-15(23)8-9-16(17)21(25)26-19(20)12-14/h8-9,11-13,23-24H,4-7,10H2,1-3H3
  • Key:BWKBVEVEQOCSCF-UHFFFAOYSA-N

AM-1714 (part of the AM cannabinoid series) is a drug that acts as a reasonably selective agonist of the peripheral cannabinoid receptor CB2, with sub-nanomolar affinity and 490x selectivity over the related CB1 receptor. In animal studies it has both analgesic and anti-allodynia effects. The 9-methoxy derivative AM-1710 has similar CB2 affinity but only 54x selectivity over CB1.[1][2]

  1. ^ Khanolkar AD, Lu D, Ibrahim M, Duclos RI, Thakur GA, Malan TP, et al. (December 2007). "Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity". Journal of Medicinal Chemistry. 50 (26): 6493–500. doi:10.1021/jm070441u. PMID 18038967.
  2. ^ Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG (November 2008). "Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 584–91. doi:10.1124/jpet.108.141994. PMC 2682949. PMID 18664590.